WO2016085530A1 - 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use - Google Patents
4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use Download PDFInfo
- Publication number
- WO2016085530A1 WO2016085530A1 PCT/US2015/000122 US2015000122W WO2016085530A1 WO 2016085530 A1 WO2016085530 A1 WO 2016085530A1 US 2015000122 W US2015000122 W US 2015000122W WO 2016085530 A1 WO2016085530 A1 WO 2016085530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- compound
- alkyl
- app2
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention is directed to a fluoro-thio-containing compound that is capable of specifically inhibiting the enzyme, membrane-bound aminopeptidase P2 (APP2), whose natural substrate is bradykinin.
- APP2 membrane-bound aminopeptidase P2
- the compound is useful as a pharmaceutical agent because by inhibiting bradykinin degradation, the compound allows endogenous bradykinin to exert its beneficial effects in the body including dilating coronary arteries, providing protective effects in the heart during myocardial ischemia/reperfusion injury, stimulating formation of new blood vessels, improving organ function in chronic heart and renal disease, and improving glucose tolerance and insulin-sensitivity.
- the present invention is also directed to a pharmaceutical composition comprising the APP2 inhibitor of the present invention and to a method of inhibiting bradykinin degradation in a mammalian patient, particularly a human patient.
- MI myocardial infarction
- bradykinin is known to prevent this kind of injury.
- bradykinin itself is not a good drug because it can seriously lower blood pressure when administered to a patient.
- Bradykinin is produced in the heart itself during ischemia and reperfusion, but doesn't increase enough to be effective. This is because bradykinin is rapidly degraded by two enzymes: membrane-bound aminopeptidase P2 (APP2) and angiotensin-converting enzyme (ACE) present on blood vessel endothelial cells. Inhibiting APP2 leads to an increase in bradykinin that prevents reperfusion injury. The biochemical mechanisms that cause reperfusion injury and those that prevent it appear to be present in most organs. Therefore, inhibiting APP2 should be protective in most situations where blood flow is stopped for a period of time (ischemia) and then restored (reperfusion).
- I/R ischemia/reperfusion
- apstatin The prototype aminopeptidase P inhibitor, apstatin (Formula I), was shown to reduce bradykinin degradation in the isolated perfused rat heart and lung. Apstatin enhanced the blood pressure-lowering effect of intravenously administered bradykinin. In a rat model of apstatin (Formula I), was shown to reduce bradykinin degradation in the isolated perfused rat heart and lung. Apstatin enhanced the blood pressure-lowering effect of intravenously administered bradykinin. In a rat model of
- Apstatin has excellent pharmacological properties and exhibits reasonable potency (micromolar), specificity and metabolic stability. However, it has chemical properties that limit its usefulness as an orally active drug. Although apstatin and related compounds have potential as injectable drugs, the potency and predicted intestinal absorption rate are probably too low to allow them to be effective following oral administration. Oral bioavailability is an essential property when the drug is being used in a chronic situation, such as adjunct treatment for hypertension or chronic heart or kidney disease. Therefore, it is an object of the present invention to discover APP2 inhibitors having greater potency ( . e., a lower IC50) than apstatin such that they can be administered in lower dosages as injectable drugs, and/or that because of their potency and chemical structure can be administered in an orally acceptable form.
- a novel compound for increasing bradykinin levels is an a-hydroxy, ⁇ -amino tripeptide to decapeptide analog, which is disclosed in U.S. Patent 5,656,603 to William H. Simmons, entitled “Aminopeptidase P inhibitors and Uses Thereof.”
- an object of the present invention is to find a compound that greatly inhibits APP2 while minimally inhibiting ACE BRIEF SUMMARY OF THE INVENTION
- the present invention is directed to a compound of Formula II:
- Ri is H or R 3 — C— ;
- alkyl or substituted alkyl having from 1 to 6 carbon atoms; or cycloalkyl-(CH 2 ) a ⁇ , aryl-(CH 2 )a— , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH 2 ) a -, having from 4 to 12 carbon atoms;
- R is alkyl or substituted alkyl, having 1-6 carbon atoms; or cycloalkyl-(CH 2 ) a ⁇ , aryl-(CH 2 )a ⁇ , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH2) a — , having from 4 to 12 carbon atoms; and
- a is zero or an integer from 1 to 6;
- the present invention is directed to a compound of Formula II:
- Ri is H, or ; R 3 -(CO)- wherein R2 is H; or alkyl having from 1 to 6 carbon atoms;
- R 3 is alkyl having from 1 to 6 carbon atoms
- the present invention is directed to a compound of Formula II: wherein Ri is H; and
- R 2 is H; or alkyl having from 1 to 6 carbon atoms;
- the present invention is directed to a compound of Formula II: wherein Ri is H; and R 2 is H;
- This compound is referred to herein as ST- 115 and also is the compound of Formula III shown below:
- the present invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of a compound of Formula II:
- Ri is H or R 3 — C— ;
- R 2 is H; alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-(CH 2 )a— , aryl-(CH 2 ) a ⁇ , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH 2 ) a ⁇ , having from 4 to 12 carbon atoms;
- R 3 is alkyl or substituted alkyl, having 1-6 carbon atoms; or cycloalkyl-(CH 2 ) a — , aryl-(CH2) a ⁇ , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH 2 ) a — , having from 4 to 12 carbon atoms; and
- a is zero or an integer from 1 to 6;
- compositions are described in the Detailed Description herein.
- the present invention is directed to a method for inhibiting bradykinin degradation in a mammalian patient, comprising administering to a mammalian patient in need of inhibition of bradykinin degradation a pharmaceutical composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of a compound of Formula II:
- Ri is H or R 3 — C— ;
- R 2 is H; alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-(CH 2 ) a — , aryl-(CH 2 ) a ⁇ , substituted aryl-(CH2) a ⁇ , or heteroaryl-(CH 2 ) a — , having from 4 to 12 carbon atoms;
- R 3 is alkyl or substituted alkyl, having 1-6 carbon atoms; or cycloalkyl-(CH 2 ) a — , aryl-(CH 2 ) a — , substituted aryl-(CH 2 ) a — , or heteroaryl-(CH 2 ) a ⁇ , having from 4 to 12 carbon atoms; and
- a is zero or an integer from 1 to 6;
- Figure 1 is a bar graph of blood urea nitrogen (BUN) concentrations (y axis) in mg/dL in mice at baseline and after treatment with saline, apstatin or ST- 115 (the compound of Formula III) during a created ischemic episode (25 minutes) but 5 minutes before reperfusion was allowed to occur.
- BUN blood urea nitrogen
- the present invention is directed to a compound of Formula II:
- Ri is H or Rj— C— ;
- R 2 is H; alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-(CH 2 )a ⁇ , aryl-(CH 2 ) a — , substituted aryl-(CH2) a ⁇ , or heteroaryl-(CH2) a ⁇ , having from 4 to 12 carbon atoms;
- R 3 is alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-
- aryl-(CH 2 )a— substituted aryl-(CH 2 ) a — , or heteroaryl-(CH 2 ) a — , having from 4 to 12 carbon atoms;
- a is zero or an integer from 1 to 6;
- pharmaceutically acceptable salt refers to relatively non-toxic, inorganic and organic base addition salts of compositions, including without limitation, analgesic agents, therapeutic agents, other materials and the like.
- pharmaceutically acceptable salts include those derived from inorganic bases, such as hydroxides, carbonates, and bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc and the like. Salts may also be formed with suitable organic bases, including those that are non-toxic and strong enough to form such salts.
- the class of such organic bases may include mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and triethylamine; mono-, di- or trihydroxyalkylamines such as mono-, di-, and triethanolamine; amino acids, such as arginine and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; (trihydroxymethyl)aminoethane; and the like. See, for example, J. Pharm. Sci., 66: 1-19 (1977).
- alkyl having from 1 to 6 carbon atoms is meant to include straight or branched chain carbon atoms.
- Typical branched chain alkyl have from three to six carbon atoms and include isopropyl, isobutyl, sec-butyl, i-butyl, isopentyl, neopentyl, cyclopentyl, isohexyl, sec-hexyl, 2,2-dimethylbutyl, 3-methylpent-3-yl, cyclohexyl and the like.
- Administering the compound of the present invention as its prodrug by injection or infusion would insure that there isn't a high concentration of the active drug at the site of injection or infusion.
- the so-administered prodrug would be diluted and distributed throughout the body before it was activated.
- One of the reasons why the genus of Formula II has several ester options is that it allows one to control the rate of prodrug activation by choosing an ester that is either rapidly (acetyl) or slowly cleaved by the esterases.
- the S-acylated prodrug form of the compound of Formula II is also chemically stable for storage, unlike the active drug, which can undergo oxidation of the free sulfhydryl (-SH) to form the disulfide homodimer (which itself would be inactive).
- acylation of both the -SH and the C-terminal carboxyl group produces a diester prodrug of Formula II that is sufficiently hydrophobic that it would be absorbed orally from the GI tract based on pharmacokinetic prediction algorithms.
- the diester can be administered to a patient in pill or syrup form.
- esterases in the patient's blood or tissue hydrolyze both of the esters, converting the thioester ' to its active sulfhydryl (-SH) form, and the carboxy ester to its free carboxy form.
- This thiol carboxy form of the compound of Formula II is the active agent of the present invention, i.e., the potent and highly selective inhibitor of APP2.
- a thioester of Formula II or Formula ⁇ is the acetylated thioester, which is the compound of Formula IV herein.
- the compound of Formula IV was made according to Example ID herein.
- the present invention is directed to a compound of Formula II:
- Ri is H, or ; R 3 -(CO)- wherein R 2 is H; or alkyl having from 1 to 6 carbon atoms;
- R 3 is alkyl having from 1 to 6 carbon atoms
- the present invention is directed to a compound of Formula II: wherein Ri is H;
- R 2 is H; or alkyl having from 1 to 6 carbon atoms;
- the present invention is directed to a compound of Formula II: wherein Ri is H; and R 2 is H;
- This compound is also referred to herein as the compound of Formula III as shown below:
- the present invention is directed to a compound of Formula II, wherein Ri is RjiCO)-; R 3 is methyl; and R 2 is H; or a pharmaceutically acceptable salt thereof.
- Ri is RjiCO
- R 3 is methyl
- R 2 is H
- a pharmaceutically acceptable salt thereof This compound is shown in the examples and also referred to herein as the compound of Formula IV:
- the compound of the present invention is useful in inhibiting bradykinin because in human model assays, the fluoro analog of Formula III of the present invention was found to selectively inhibit the enzyme human APP2 but not the enzyme human ACE when compared to three non-fluoro peptide analogs (the compounds of Formulas V, VI and VII) of the closest prior art, US Pat. 7,390,789 (Simmons). All asymmetric carbon atoms in the compounds of Formulas V, VI and VII are in the ⁇ -configuration unless otherwise noted.
- the methods for determining the APP2 and ACE inhibitory activities of the peptide analogs are described in Examples 2 and 3 herein. The comparative data is reported in Table 1 herein.
- Table 1 compares the chemical structure of each compound tested, its ICso (nM/L) for AAP2, its IC50 for ACE and then the compound's ratio of IC50S for ACE/AAP2. The compounds were then arranged in descending order in Table 1 based upon their decreasing selectivity as calculated by their IC50 ratios for ACE/AAP2.
- the compound of Formula III of the present invention having the 4(S)-fluoro, exhibited a superior ability to inhibit human APP2 (IC50 of 3.7 nM/L) and a superior inability to inhibit human ACE (IC50 of 68,000 nM/L). This is reflected in the compound's IC50 ratio for ACE/AAP2 of 18,000. The next best ratio by a comparative compound lacking the 4(S)-fluoro was provided by the prior art compound of Formula V wherein the IC50 ratio was 1,900. Comparative compounds of Formulas VI and VII had substantially smaller IC50 ratios for ACE/AAP2 of 1,200 and 160, respectively.
- FIG. 1 shows that both apstatin and ST- 1 15 (the compound of Formula III) can also reduce ischemia/reperfusion damage in the kidney.
- apstatin, ST-115, or saline were administered intravenously 5 min. before reperfusion. After two days of reperfusion, blood urea nitrogen (BUN, a marker of kidney dysfunction) was measured.
- BUN blood urea nitrogen
- FIG. 1 shows that the saline-treated mice had very high BUN values compared to baseline values in mice, indicating major kidney damage. Compared to saline, apstatin reduced BUN by 49%, while ST-115 reduced it by 56%. In addition, 29% of saline control mice died before the prespecified 2-day BUN measurement point, while no apstatin or ST- 115 treated mice died early. The fact that apstatin and ST-115 were protective when given just before reperfusion suggest that they are specifically blocking reperfusion damage rather than ischemic damage in this model.
- the 4(S)-fluoro compound of Formula III, and the related 4(S)-fluoro compounds of Formula II would be useful as a pharmaceutical agent in a method for blocking reperfusion injury to tissue in a mammalian patient. In a more preferred embodiment, they would be useful as pharmaceutical agents administered to a mammalian patient in a method for blocking reperfusion injury to the heart or kidney of a mammalian patient.
- Apstatin and the compound of Formula III are structurally different molecules that both inhibit APP2. The fact that both had similar protective effects suggest that their mechanism of action is similar, i.e., the inhibition of endogenous APP2.
- a functional difference between the two is that the compound of Formula III had an effect at a dose that was 180-fold lower than that of apstatin, which is consistent with the large difference in their IC50 values for inhibiting APP2 in vitro.
- the fact that APP2 inhibition can reduce reperfusion damage in both heart and kidney suggests that the mechanisms for both producing and blocking reperfusion damage may be redundant and present in many other, if not all, tissues in the body. Therefore, the 4(S)-fluoro compound of Formula III, and the related 4(S)-fluoro compounds of Formula II should be useful for blocking many types of ischemia/reperfusion injury.
- the present invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of a compound of Formula II:
- Ri is H or R3— C— ;
- R 2 is H; alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-(CH 2 ) a ⁇ , aryl-(CH 2 ) a ⁇ , substituted aryl-(CH2) a ⁇ , or heteroaryl-(CH2) a ⁇ , having from 4 to 12 carbon atoms;
- R3 is alkyl or substituted alkyl, having 1-6 carbon atoms; or cycloalkyl-(CH 2 ) a ⁇ , aryl-(CH 2 ) a ⁇ , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH 2 ) a ⁇ , having from 4 to 12 carbon atoms; and
- a is zero or an integer from 1 to 6;
- the term "therapeutically effective amount” as used herein means that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system or animal that is being sought by a researcher or clinician. An effective but nontoxic quantity of the compound is employed in treatment.
- the dosage regimen for preventing or treating symptoms by the compounds of this invention is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the mammal, the severity of the symptoms, the route of administration of the particular compound employed. An ordinary skilled physician or veterinarian will readily determine and prescribe the effective amount based on the route of administration of the agent to prevent or arrest the progress of the condition. In so proceeding, the physician or veterinarian employs relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained.
- bradykinin potentiation by apstatin has been observed with 0.08-0.8 mg/kg intravenously when administered over a one hour period.
- More potent inhibitors of the present invention should be effective at ten- to one hundred eighty-fold lower dosages. See e.g., Table 1. Less potent inhibitors would require a greater dosage to provide the same therapeutic result.
- a typical therapeutically effective dose of a compound of the present invention is from about 0.0003 mg/kg to 0.8 mg/kg, when given intravenously.
- a non-toxic but therapeutically effective quantity of one or more compounds of this invention is employed in any treatment.
- a dosage is selected in accordance with a variety of factors, including the type, age, weight, sex, and medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed in the treatment.
- a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent or arrest the progress of the condition. In so proceeding, the physician or veterinarian could employ relatively low doses at first and subsequently increase the dose until a maximum response is obtained.
- oral dosages vary depending upon the IC50 of the compound of the invention. However, oral dosages are ordinarily in the range of about 0.1 mg/kg up to about 200 mg/kg, (preferably, in the range of about 2.0 to 84.0 mg/kg (orally)).
- pharmaceutically acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a dispersion or suspension aid, surface active agent, pH modifier, isotonic agent, thickening or emulsifying agent, preservative, solid binder, lubricant and the like, as suited to the particular dosage form desired. Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A.
- Gennaro, Lippincott Williams & Wilkins, 2000 discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Also, Strickley, Pharmaceutical Research, 21(2) 201-230 (2004) reviews pharmaceutically acceptable excipients used in commercial products to solubilize compounds for oral or parenteral administration. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
- materials which can serve as a pharmaceutically acceptable carrier include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, carbonates, magnesium hydroxide and aluminum hydroxide, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, pyrogen-free water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat; sugars such as lactose, glucose, sucrose, and mannitol; starches such as corn starch and potato starch, cellulose and its derivatives such as sodium carboxymethyl cellulose, ethoxymethyl
- compositions are manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, or emulsifying processes, among others.
- Compositions may be produced in various forms, including granules, precipitates, or particulates, powders, including freeze dried, rotary dried or spray dried powders, amorphous powders, tablets, capsules, syrup, suppositories, emulsions, elixirs, suspensions or solutions.
- the compound of the present invention When combined with a pharmaceutically acceptable carrier, the compound of the present invention is suited for administration orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, or topically using a liquid carrier form known to the pharmaceutical arts and as described below.
- the pharmaceutical composition of the present invention may be administered rectally or vaginally, in such forms as suppositories or bougies.
- the preferred forms of the pharmaceutical composition are formulated for oral or intravenous administration, more typically for oral administration.
- the foregoing active compounds described herein are typically provided in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as "carrier” materials) suitably selected with respect to the intended mode and form of administration, that is, oral tablets, capsules, softgels, elixirs, syrups, drops, and the like, and consistent with well known pharmaceutical practices.
- carrier suitable pharmaceutical diluents, excipients, or carriers
- a therapeutically effective amount of one or more compounds of the present invention are combined with any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate mannitol, and the like, or various combinations thereof.
- any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate mannitol, and the like, or various combinations thereof.
- a therapeutically effective amount of the active drug components is combined with any oral non-toxic pharmaceutically acceptable inert carrier such as water, saline, ethanol, polyethylene, glycol, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, various buffers, and the like, or a combination thereof.
- suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated in the mixture.
- Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol, and waxes, or combinations thereof.
- Lubricants for use in these dosage forms include boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like, or combinations thereof.
- Disintegrators include, without limitation, starch, methylcellulose, agar, bentonite, guar gum, and the like, or combinations thereof. Sweetening and flavoring agents and preservatives can also be included where appropriate.
- one or more compounds of the present invention are combined with a suitable carrier such as water, isotonic saline, aqueous dextrose, and the like.
- a suitable carrier such as water, isotonic saline, aqueous dextrose, and the like.
- topical administration one or more compounds of the present invention can be combined with pharmaceutically acceptable creams, oils, waxes, gels and the like.
- the compounds of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those skilled in the art.
- the compounds may also be formulated using pharmacologically acceptable base addition salts.
- the compounds or their salts may be used in a suitable hydrated form.
- the compounds of Formula II are useful in inhibiting the breakdown of bradykinin (Bk), which in turn has the beneficial effects of dilating the arteries (such as the renal and coronary arteries as already discussed herein), reducing cardiac ischemia/reperfusion injury, stimulating the formation of new blood vessels, and increasing renal perfusion and function.
- the compounds of the present invention are useful as the active agent in a pharmaceutical composition for inhibiting the breakdown of bradykinin, for treating hypertension, for treating myocardial ischemia/reperfusion injury, or for enhancing renal function in a mammalian patient, preferably a human patient.
- a physician or veterinarian of ordinary skill can readily determine whether a patient exhibits hypertension, myocardial ischemia, or diminished renal function.
- the preferred utility relates to reducing ischemia/reperfusion injury in a mammalian patient.
- mammalian patient as used herein is meant a mammal in need of treatment such as a rat, mouse, horse, cow, pig, goat, sheep, or primate.
- the mammalian patient is a primate. More preferably, the primate is a human.
- the pharmaceutical composition of the present invention is a compound of Formula II:
- Ri is H, or ; R 3 -(CO)- wherein R 2 is H; or alkyl having from 1 to 6 carbon atoms; wherein R3 is alkyl having from 1 to 6 carbon atoms;
- the pharmaceutical composition of the present invention is a compound of Formula II:
- R2 is H; or alkyl having from 1 to 6 carbon atoms;
- the pharmaceutical composition of the present invention is a compound of Formula II:
- Ri is H; and R 2 is H;
- This compound is referred to herein as ST- 115 and also is the compound of Formula III.
- the present invention is directed to a method for inhibiting bradykinin degradation in a mammalian patient, comprising administering to a mammalian patient in need of inhibition of bradykinin degradation a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a therapeutically effective amount of a compound of Formula II:
- Ri is H or R3— C— ;
- R 2 is H; alkyl or substituted alkyl, having from 1 to 6 carbon atoms; or cycloalkyl-(CH2)a ⁇ , aryl-(CH 2 ) a ⁇ , substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH 2 ) a ⁇ , having from 4 to 12 carbon atoms;
- R3 is alkyl or substituted alkyl, having 1-6 carbon atoms; or cycloalkyl-(CH 2 ) a ⁇ , aryl-(CH 2 )a-, substituted aryl-(CH 2 ) a ⁇ , or heteroaryl-(CH2)a ⁇ , having from 4 to 12 carbon atoms; and
- a is zero or an integer from 1 to 6;
- the pharmaceutical composition is a compound of Formula II:
- Ri is H, or ; R 3 -(CO)- wherein R 2 is H; or alkyl having from 1 to 6 carbon atoms;
- R 3 is alkyl having from 1 to 6 carbon atoms
- the pharmaceutical composition is a compound of Formula II:
- R 2 is H; or alkyl having from 1 to 6 carbon atoms;
- the pharmaceutical composition is a compound of Formula II:
- Ri is H; and R 2 is H;
- This compound is referred to herein as ST- 1 15 and also is the compound of Formula III.
- the method of inhibiting bradykinin degradation in the mammalian patient is associated with preventing or ameliorating reperfusion injury in the mammalian patient following an ischemic episode.
- the tissue in the mammalian patient that is subject to the reperfusion injury following an ischemic episode is kidney, lung, liver, myocardium, brain, limb or the whole body following cardiac arrest.
- the tissue is the kidney or the myocardium. More preferably, the tissue is the myocardium.
- the resin was washed with DMF (3 x 30 mL) and dichloromethane (3 x 30 mL), and then was cleaved with 1% trifluoroacetic acid/dichloromethane (TFA/DCM) (150 mL) for 1 hour at room temperature.
- the resin was removed by filtration under reduced pressure and washed with 1%TFA/DCM (50 mL).
- the filtrates were combined and concentrated to a glassy film on a rotary evaporator below 30°C.
- Cold diethyl ether (30 mL) was added to precipitate the peptide.
- the peptide was collected by filtration and washed with cold ether (2 x 5 mL). After drying, the crude titled peptide (670 mg) was obtained.
- Human kidney tissue which was obtained from the Cooperative Human Tissue Network, was the source of purified human APP2 as used herein. APP2 enzyme activity was measured during purification as described in Example 2B below.
- the membrane-bound APP2 was purified from human kidney tissue using the following steps: 1) kidney tissue was homogenized in 30 volumes of buffer containing Triton X-100 detergent and centrifuged; 2) the pellet was washed and suspended in buffer containing octyl-P-D- glucopyranoside detergent, and then centrifuged; 3) the supernatant was treated with 10 units of phosphatidylinositol-specific phospholipase C (Invitrogen, Eugene, GA) to remove the hydrophobic part of the glycosyl-phosphatidylinositol lipid membrane anchor from APP2, and then dialyzed; 4) the dialysate was passed through an octyl-Sepharose chromatography column; 5) the el
- Enzyme rates were determined in an Fmax fluorescence plate reader (Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 320 nm and an emission wavelength of 405 nm.
- the binding affinity of an inhibitor was estimated and expressed as IC50 values (the concentration that inhibits activity by 50%).
- hrACE Human recombinant angiotensin-converting enzyme
- Enzyme rates were determined in an rma fluorescence plate reader (Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 320 nm and an emission wavelength of 405 nm.
- the binding affinity of an inhibitor was estimated and expressed as IC50 values (the concentration that inhibits activity by 50%).
- mice Male CD-I (ICR) mice (36-47 g) from Harlan Laboratories (Indianapolis, IN) were used. Each mouse was anesthetized by the subcutaneous injection of 50 mg/kg sodium pentobarbital (Akorn Inc, Lake Forest, IL) and placed on a 37° C warmer. For surgery, the abdomen was shaved and the mouse was moved to a warming plate with feedback temperature control (TCAT-2DF, Harvard Apparatus Holliston, MA). The body temperature of the mouse was maintained at 36.9 ⁇ 0.1° C throughout the procedure. The skin of the abdomen was washed with alcohol, and a midline incision was made to expose the kidneys.
- TCAT-2DF Harvard Apparatus Holliston
- a microaneurysm clamp was placed on each pedicle to block blood flow to/from both kidneys for 25 min. (referred to as the ischemia phase).
- 0.15 ml of either saline or saline containing drug (apstatin or ST-115) was administered intravenously through the femoral vein.
- the doses were 1.8 mg/kg for apstatin and 10 ⁇ g/kg for ST-115.
- the clamps were removed from the pedicles to restore blood flow to/from the kidneys (the reperfusion phase).
- the BUN data points (20) were analyzed by comparing the values for each drug with those of the saline control using the unpaired t-test with Welch's correction (Graphpad Prism statistical package, La Jolla, CA). BUN values for mice that did not undergo the ischemia/reperfusion protocol were obtained to demonstrate "baseline" concentrations of urea.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015354761A AU2015354761B2 (en) | 2014-11-24 | 2015-10-30 | 4-fluoro-thio-containing inhibitors of APP2, compositions thereof and method of use |
CA2968825A CA2968825C (en) | 2014-11-24 | 2015-10-30 | 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use |
JP2017524480A JP6342585B2 (en) | 2014-11-24 | 2015-10-30 | 4-Fluoro-thio-containing APP2 inhibitors, compositions thereof, and methods of use |
EP15862635.8A EP3223613B1 (en) | 2014-11-24 | 2015-10-30 | 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/544,096 US9212206B1 (en) | 2014-11-24 | 2014-11-24 | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use |
US14/544,096 | 2014-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016085530A1 true WO2016085530A1 (en) | 2016-06-02 |
Family
ID=54783087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/000122 WO2016085530A1 (en) | 2014-11-24 | 2015-10-30 | 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use |
Country Status (6)
Country | Link |
---|---|
US (1) | US9212206B1 (en) |
EP (1) | EP3223613B1 (en) |
JP (1) | JP6342585B2 (en) |
AU (1) | AU2015354761B2 (en) |
CA (1) | CA2968825C (en) |
WO (1) | WO2016085530A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9212206B1 (en) * | 2014-11-24 | 2015-12-15 | William H Simmons | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684660A (en) * | 1979-04-02 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Mercaptoacyldepeptides |
US7390789B2 (en) * | 2005-09-13 | 2008-06-24 | William H Simmons | Thio-containing inhibitors of aminopeptidase P, and compositions thereof |
US9212206B1 (en) * | 2014-11-24 | 2015-12-15 | William H Simmons | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507312A (en) | 1979-07-13 | 1985-03-26 | Usv Pharmaceutical Corporation | Antihypertensive amides |
US4549992A (en) | 1979-07-13 | 1985-10-29 | Usv Pharmaceutical Corp. | Antihypertensive amides |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US5656603A (en) | 1995-05-31 | 1997-08-12 | Loyola University Of Chicago | Aminopeptidase P inhibitors and uses thereof |
US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
-
2014
- 2014-11-24 US US14/544,096 patent/US9212206B1/en active Active
-
2015
- 2015-10-30 CA CA2968825A patent/CA2968825C/en active Active
- 2015-10-30 WO PCT/US2015/000122 patent/WO2016085530A1/en active Application Filing
- 2015-10-30 EP EP15862635.8A patent/EP3223613B1/en active Active
- 2015-10-30 AU AU2015354761A patent/AU2015354761B2/en active Active
- 2015-10-30 JP JP2017524480A patent/JP6342585B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684660A (en) * | 1979-04-02 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Mercaptoacyldepeptides |
US7390789B2 (en) * | 2005-09-13 | 2008-06-24 | William H Simmons | Thio-containing inhibitors of aminopeptidase P, and compositions thereof |
US9212206B1 (en) * | 2014-11-24 | 2015-12-15 | William H Simmons | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use |
Also Published As
Publication number | Publication date |
---|---|
CA2968825C (en) | 2019-07-02 |
EP3223613A1 (en) | 2017-10-04 |
US9212206B1 (en) | 2015-12-15 |
JP6342585B2 (en) | 2018-06-13 |
CA2968825A1 (en) | 2016-06-02 |
AU2015354761B2 (en) | 2018-04-05 |
JP2017536355A (en) | 2017-12-07 |
EP3223613A4 (en) | 2018-07-18 |
AU2015354761A1 (en) | 2017-05-18 |
EP3223613B1 (en) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015002848A (en) | Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof. | |
HU192646B (en) | Process for preparing new n-alkyl-peptide aldehydes | |
RU2151776C1 (en) | Cyclopeptides and method of preparation thereof | |
RU2660901C2 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
JPH03386B2 (en) | ||
WO1997009346A1 (en) | Des-arg9-bk antagonists | |
KR100251496B1 (en) | Hexapeptide | |
AU2015354761B2 (en) | 4-fluoro-thio-containing inhibitors of APP2, compositions thereof and method of use | |
AU684511B2 (en) | Oligopeptides derived from C-reactive protein fragments | |
CA2621262C (en) | Thio-containing inhibitors of aminopeptidase p, compositions thereof and method of use | |
JP2007182414A (en) | New dried bonito peptide, l-valyl-l-proline and antihypertensive agent | |
JP3893579B2 (en) | Novel tetrapeptide and angiotensin converting enzyme inhibitors | |
JP3009718B2 (en) | New peptides, their production methods and applications | |
JP3129523B2 (en) | Novel peptide and method for producing the same | |
JP3709425B2 (en) | Novel tripeptide and angiotensin converting enzyme inhibitors | |
JP3220420B2 (en) | Pentapeptide, its production method and its use | |
JP3009720B2 (en) | New peptides, their production methods and applications | |
JP3086235B2 (en) | New peptides and applications | |
JP2953634B2 (en) | New peptides, their production methods and applications | |
JP3992143B2 (en) | Novel bioactive peptide | |
JP2922247B2 (en) | Angiotensin converting enzyme inhibitor | |
JP3305291B2 (en) | Production method of peptide | |
JPH03197493A (en) | Novel peptide | |
JPH0959296A (en) | New tetrapeptide and angiotensin converting enzyme inhibitory agent | |
AU2007285045A1 (en) | Cardioprotective compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15862635 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017524480 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015354761 Country of ref document: AU Date of ref document: 20151030 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2968825 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015862635 Country of ref document: EP |